ストックスクリーナーアプリを入手
9.30
2.76%
0.25
前日終値:
$9.05
開ける：
$9.05
24時間の取引高:
684.83K
Relative Volume:
0.82
時価総額：
$614.27M
収益：
$301.79M
当期純損益:
$-43.42M
株価収益率:
-13.87
EPS:
-0.6705
ネットキャッシュフロー:
$-44.87M
1週間 パフォーマンス:
+4.73%
1か月 パフォーマンス:
+51.96%
6か月 パフォーマンス:
+66.37%
1年 パフォーマンス:
+23.83%
1日の値動き範囲:
$8.975
$9.31
1週間の範囲:
$8.75
$9.31
52週間の値動き範囲:
$3.86
$9.31
Evolus Inc Stock (EOLS) Company Profile
Compare EOLS vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
9.30 | 551.52M | 301.79M | -43.42M | -44.87M | -0.6705 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | ダウングレード | Needham | Buy → Hold |
| 2025-04-17 | 開始されました | BTIG Research | Buy |
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 開始されました | Needham | Buy |
| 2022-05-12 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2021-05-06 | アップグレード | Mizuho | Neutral → Buy |
| 2021-04-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-24 | ダウングレード | Truist | Buy → Hold |
| 2020-07-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-02-06 | 再開されました | Mizuho | Buy |
| 2019-11-26 | 開始されました | SVB Leerink | Outperform |
| 2019-09-05 | 再開されました | Mizuho | Buy |
| 2019-06-28 | 開始されました | Wells Fargo | Market Perform |
| 2019-06-11 | 開始されました | Barclays | Underweight |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-29 | 開始されました | Stifel | Buy |
すべてを表示
Evolus Inc (EOLS) 最新ニュース
Evolus (EOLS) Quarter in Focus: EPS Comes in Above Forecast on the Day; Share Move - vinanet.vn
Evolus (EOLS) Closing Note: Records a 5.28% Increase to $8.18 in the Latest Session; the Price Remains Bounded by the Supplied Support and Resistance in the Available RecordBearish Sentiment - vinanet.vn
EOLS Q2 2026 Earnings: EPS Turns Positive, Delivering 156.82% Surprise vs. EstimatesCost Structure Review - vinanet.vn
August 2026's Leading Growth Companies With Insider Confidence - Sahm
Midday Stock Roundup: Mobix Labs Shares Fall 21% at Midday - ocbj.com
Renaissance Technologies LLC Lowers Stake in Evolus, Inc. $EOLS - marketbeat.com
Evolus, Inc. (EOLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS - marketbeat.com
EOLS Q2 2026 Earnings: EPS Surprises to the Upside as Shares SlipReturn On Equity - vinanet.vn
Evolus (NASDAQ:EOLS) Reaches New 1-Year HighHere's What Happened - MarketBeat
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade - Yahoo Finance
Evolus: The Injectable Platform Is Becoming The Real Moat (NASDAQ:EOLS) - Seeking Alpha
EOLS Q2 2026 Earnings: EPS Hits $0.02, Marking 156.82% Beat and 3.83% Stock AdvancePositive Surprise Momentum - vinanet.vn
EOLS Q2 2026 Earnings: EPS of $0.02 Beats Estimates by 156.8% as Profitability Inflection EmergesSpecial Dividend Alert - vinanet.vn
Trading Systems Reacting to (EOLS) Volatility - Stock Traders Daily
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen - marketbeat.com
Needham Maintains Evolus(EOLS.US) With Hold Rating - moomoo.com
BTIG Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Evolus Inc (EOLS) Stock News Today - TradingKey
Evolus, Inc. (EOLS) Investor Outlook: Analyzing 97.93% Potential Upside in the Aesthetic Market - DirectorsTalk Interviews
Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Su - GuruFocus
Earnings call transcript: Evolus tops revenue forecast in Q2 2026, shares rise - Investing.com UK
Evolus, Inc. Q2 2026 Financial Results: Revenue, Risks, and Key Business Updates - Minichart
Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ... - Yahoo Finance
Evolus Q2 Earnings Call Highlights - MarketBeat
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2 - Yahoo Finance
Is Evolus Inc (EOLS) Undervalued After Q2 Earnings Beat? EPS: -0 - GuruFocus
Evolus Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Evolus Q2 2026 slides: profitability streak continues, guidance raised - Investing.com
Evolus, Inc. Q2 2026: Revenue $84.08M, EPS ($0.12) — 10-Q Summary - TradingView
Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses - Quiver Quantitative
Evolus (Nasdaq: EOLS) posts higher sales and manages sizable debt load - stocktitan.net
Evolus Q2 revenue rises 21%, lifts 2026 outlook - TradingView
Evolus Q2 2026 Earnings: Revenue Rises 21% as Adjusted EBITDA Stays Positive - TradingKey
Evolus (NASDAQ: EOLS) lifts 2026 guidance after Q2 revenue hits $84.1 million - Stock Titan
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook - marketscreener.com
Evolus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Evolus, Inc. Reaffirms Earnings Guidance for the Year 2028 - marketscreener.com
Evolus Deadline Alert - TMX Newsfile
Evolus Expands Symatese Partnership into Three New Markets - Orange County Business Journal
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme in Canada, Australia, and New Zealand - marketscreener.com
Evolus expands hyaluronic acid gel rights to three markets By Investing.com - Investing.com Nigeria
Evolus expands hyaluronic acid gel rights to three markets - Investing.com
Evolus, Inc. (NASDAQ: EOLS) extends Estyme deal to $500M markets - Stock Titan
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand - Yahoo Finance
Evolus Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Perceptive Advisors LLC Acquires New Stake in Evolus, Inc. $EOLS - MarketBeat
Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Evolus (EOLS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Evolus Inc (EOLS) 財務データ
収益
当期純利益
現金流量
EPS
Evolus Inc (EOLS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID | See Remarks |
Mar 20 '26 |
Sale |
4.75 |
13,669 |
64,929 |
604,700 |
| MOATAZEDI DAVID | See Remarks |
Mar 16 '26 |
Option Exercise |
0.00 |
67,489 |
0 |
735,089 |
| MOATAZEDI DAVID | See Remarks |
Mar 17 '26 |
Sale |
4.89 |
116,720 |
570,562 |
618,369 |
| Avelar Rui | See Remarks |
Mar 16 '26 |
Option Exercise |
0.00 |
8,804 |
0 |
460,538 |
| Avelar Rui | See Remarks |
Mar 17 '26 |
Sale |
4.89 |
29,996 |
146,629 |
430,542 |
| MOATAZEDI DAVID | See Remarks |
Dec 22 '25 |
Sale |
7.15 |
10,539 |
75,361 |
354,388 |
| Avelar Rui | See Remarks |
Dec 22 '25 |
Sale |
7.15 |
2,261 |
16,168 |
356,821 |
1.66%
0.33%
大文字化:
|
ボリューム (24 時間):